"In 2020, we continued to take major steps in the transformation of the company and expanded beyond our traditional stronghold in haemophilia. We achieved solid growth during the year, and broadened the foundation of the company to align with our ambition of becoming a global leader in rare disease," said
Sobi's 2020 Annual and Sustainability Report is available on sobi.com.
About Sobi™
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Sobi employs approximately 1,500 people across
For more information, please contact
Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
paula.treutiger@sobi.com
+ 46 767 248 830
maria.kruse@sobi.com
Postal address SE-112 76
Phone: 46 8 697 20 00 www.sobi.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi--publishes-2020-annual-and-sustainability-report,c3319617
https://mb.cision.com/Main/14266/3319617/1397064.pdf
(c) 2021 Cision. All rights reserved., source